IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?
Journal of Clinical Medicine · 06.06.2026 · 15 (12) · 4408
DOI: 10.3390/jcm15124408 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.06.2026. Verfasst von Mohammad Alsaeid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn’s disease can be associated with other immune-mediated inflammatory diseases (IMIDs) and extraintestinal manifestations (EIM) including dermatological manifestations, ophthalmologic manifestations, musculoskeletal manifestations and neurological manifestations. The aim of this narrative review is to discuss the optimal management and treatment strategy of IBD with immune-mediated inflammatory disease and extraintestinal manifestations.
Methods
This review is based on published studies searched in PubMed until 31 December 2025. Our search focused on systemic reviews, review articles, randomized trials, cohort studies, guidelines and case series.
Results
In IBD, the presence of additional immune-mediated inflammatory diseases (IMIDs) should be considered a poor prognostic factor, prompting closer disease monitoring and earlier escalation to or optimization of advanced therapy. Therapeutic management requires careful consideration including a multidisciplinary approach and a selection of the most appropriate treatment option(s) based on the presence, severity of IBD and/or IMIDs and/or EIM. For patients with refractory disease affecting multiple organs, emerging strategies include dual biologic therapies.
Conclusions
The optimal management of IBD with associated IMIDs/EIM should be multidisciplinary in close cooperation among specialists to align treatment goals and management plans.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada.
- Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
ORCID-Profile: Talat Bessissow, Peter L Lakatos
Zitieren
APA
Alsaeid, M., Abu Hawi, O., Bessissow, T., & Lakatos, P. L. (2026). IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?. Journal of Clinical Medicine, 15(12), 4408. https://doi.org/10.3390/jcm15124408
Vancouver
Alsaeid M, Abu Hawi O, Bessissow T, Lakatos PL. IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?. Journal of Clinical Medicine. 2026;15(12):4408. doi:10.3390/jcm15124408
BibTeX
@article{Alsaeid2026,
author = {Alsaeid, Mohammad and Abu Hawi, Osamah and Bessissow, Talat and Lakatos, Peter L},
title = {IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4408},
doi = {10.3390/jcm15124408}
}
EUVIMED